Related Experiment Video
Updated: Jan 23, 2026

Phosphoproteomic Strategy for Profiling Osmotic Stress Signaling in Arabidopsis
Published on: June 25, 2020
LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance
Owen F J Hovey1, Mallory I Frederick1, Quan M Quach1
1Department of Biochemistry, Western University, London, Ontario, Canada.
Abstract:
Chronic myeloid leukemia (CML) resistance to BCR-ABL tyrosine kinase inhibitors can arise from ABL kinase domain mutations, BCR-ABL fusion gene amplification, or kinase-independent mechanisms. To investigate imatinib-resistance, we performed quantitative mass spectrometry comparing the proteome and phosphoproteome of K562 cells (a standard CML model) and ImR cells, an imatinib-resistant K562 derivative that also exhibits cross-resistance to second- and third-generation BCR-ABL tyrosine kinase inhibitors. In addition to revealing global proteome and phosphoproteome changes associated with drug resistance, we identified LIN28A-a multifunctional RNA-binding protein-as a critical mediator of imatinib resistance. LIN28A was significantly overexpressed and hyperphosphorylated in ImR cells. Depleting LIN28A via shRNA restored imatinib sensitivity, while its ectopic expression in parental K562 cells induced imatinib resistance. Mechanistically, LIN28A coordinates an extensive kinase-substrate network regulating proliferation, survival, and metabolism to drive resistance. Notably, pharmacological inhibition of LIN28A-dependent kinases (PKC, AKT, SGK1, and RPS6K) suppressed ImR proliferation. Midostaurin, a clinical PKC/FLT3 inhibitor used in FLT3-ITD-positive AML, potently resensitized ImR cells to imatinib. Our findings suggest that targeting LIN28A and its downstream effectors, particularly PKC, could overcome resistance to imatinib and next-generation BCR-ABL inhibitors.
Insights
LIN28A, a protein overexpressed in imatinib-resistant chronic myeloid leukemia (CML), drives resistance by coordinating kinase networks. Targeting LIN28A or its downstream kinases, like PKC, can overcome resistance to BCR-ABL tyrosine kinase inhibitors (TKIs).
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Resistance to BCR-ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is a significant clinical challenge.
- Mechanisms of TKI resistance include BCR-ABL kinase domain mutations, gene amplification, and kinase-independent pathways.
- Understanding novel resistance mediators is crucial for developing effective CML therapies.
Purpose of the Study:
- To investigate the proteomic and phosphoproteomic changes associated with imatinib resistance in CML.
- To identify novel molecular targets that mediate resistance to BCR-ABL TKIs.
- To explore therapeutic strategies for overcoming TKI resistance in CML.
Main Methods:
- Quantitative mass spectrometry was used to compare the proteome and phosphoproteome of imatinib-sensitive (K562) and imatinib-resistant (ImR) CML cells.
- RNA interference (shRNA) was employed to deplete LIN28A expression.
- Ectopic expression of LIN28A was performed in parental K562 cells.
- Pharmacological inhibitors targeting LIN28A-dependent kinases were utilized.
Main Results:
- LIN28A was identified as a critical mediator of imatinib resistance, significantly overexpressed and hyperphosphorylated in ImR cells.
- Depletion of LIN28A restored imatinib sensitivity, while its ectopic expression induced resistance.
- LIN28A coordinates a kinase-substrate network regulating proliferation, survival, and metabolism, driving resistance.
- Pharmacological inhibition of LIN28A-dependent kinases (PKC, AKT, SGK1, RPS6K) suppressed ImR cell proliferation.
- Midostaurin, a PKC/FLT3 inhibitor, re-sensitized ImR cells to imatinib.
Conclusions:
- LIN28A is a key driver of imatinib resistance in CML, acting through extensive kinase signaling networks.
- Targeting LIN28A and its downstream effectors, particularly protein kinase C (PKC), represents a promising strategy to overcome resistance to BCR-ABL TKIs.
- Midostaurin shows potential in combination therapy to re-sensitize CML cells to imatinib and next-generation TKIs.
Related Concept Videos
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Resistivity
Resistance
Frequency-dependent Selection
Introduction to Nuclear Reprogramming

